Research map: Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib

Back to the article

Papers in this map

  1. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review · Zahari Vinarov · 2021 · 359 citations · Cited by this paper
  2. Retrospective study on regional nodal irradiation after omission of axillary lymph node dissection in sentinel lymph node-positive breast cancer: a propensity score matching analysis · 2026 · Related
  3. The genetic basis of variability in drug responses · Dan M. Roden · 2002 · 293 citations · Cited by this paper
  4. Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care · 2026 · Related
  5. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib · Benoit Beuselinck · 2013 · 97 citations · Cited by this paper
  6. Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer · 2026 · Related
  7. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions · Rossana Roncato · 2020 · 85 citations · Cited by this paper
  8. Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study · 2026 · Related
  9. Impact of Acid‐Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH‐Dependent Solubility, With Different Food Intake Conditions · Wan Sun · 2017 · 84 citations · Cited by this paper
  10. Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B) · 2026 · Related
  11. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients · Marzia Del Re · 2021 · 60 citations · Cited by this paper
  12. Age-stratified difference in patient-reported health-related quality of life following breast cancer surgery · 2026 · Related
  13. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel · Tülay Kuş · 2016 · 58 citations · Cited by this paper
  14. Rediscovering the Ciucci pathway: in-vivo evidence of a palmar lymphatic channel · 2026 · Related
  15. Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure · Jean‐Luc Raoul · 2023 · 54 citations · Cited by this paper
  16. Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer · 2026 · Related
  17. Early treatment-related neutropenia predicts response to palbociclib · Nicholas Patrick McAndrew · 2020 · 41 citations · Cited by this paper
  18. Impact of axillary surgery on survival in de novo metastatic breast cancer with primary tumor resection · 2026 · Related
  19. Human constitutive androstane receptor mediated methotrexate induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1) · Xi Chen · 2006 · 37 citations · Cited by this paper
  20. Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer · 2026 · Related
  21. Pregnane X Receptor (PXR) Polymorphisms and Cancer Treatment · Aikaterini Skandalaki · 2021 · 30 citations · Cited by this paper
  22. Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3 · Hiroji Iwata · 2021 · 29 citations · Cited by this paper
  23. An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer · Rossana Roncato · 2022 · 26 citations · Cited by this paper
  24. Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients · Litaty Mbatchi · 2016 · 25 citations · Cited by this paper
  25. Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration · Jean‐Luc Raoul · 2024 · 22 citations · Cited by this paper
  26. Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer · Elena Peruzzi · 2023 · 16 citations · Cited by this paper
  27. Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects · Fanny Leenhardt · 2022 · 14 citations · Cited by this paper
  28. Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer · Perrine Courlet · 2022 · 13 citations · Cited by this paper
  29. Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis · Francisco Cézar Aquino de Moraes · 2024 · 12 citations · Cited by this paper
  30. Pharmacogenetics and Pharmacokinetics Modeling of Unexpected and Extremely Severe Toxicities After Sorafenib Intake · Hai le Ba · 2020 · 11 citations · Cited by this paper
  31. PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L) · Veronique C Dieras · 2017 · 8 citations · Cited by this paper
  32. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer · Serena Di Cosimo · 2024 · 6 citations · Cited by this paper
  33. Enhancing breast cancer treatment through pharmacogenomics: A narrative review · Ram Mohan Ram Kumar · 2024 · 6 citations · Cited by this paper
  34. Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity · Chong Wang · 2024 · 4 citations · Cited by this paper
  35. Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast · Javier Álvarez Criado · 2024 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)